Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
You have tolerated the current dose with minimal or no GI side effects for at least two consecutive weeks
First, well conduct a consultation to determine whether youre an eligible candidate
Individual variation is significant, with factors like age, baseline condition, and protocol adherence affecting timelines
Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) 1 ipilimumab (IPI): CheckMate 142
US$ 24.92
US$ 27.49
US$ 28.43
US$ 22.82
US$ 26.75
US$ 22.48
US$ 24.88
US$ 25.99
